On Tuesday, a patient presented with a problematic left knee. She had been walking her dogs when she was attacked by a pit bull. In escaping, her left knee twisted violently, and over the past several weeks, the pain, limp, and swelling have remained. In reviewing her medical records, I was reminded that in 2012, she became the 40th patient I had treated with a Bone Marrow Concentrate for an osteoarthritic knee.
Fast forward to 02/09/2021, until the recent traumatic event, the patient has been symptom-free without limitation of function or lifestyle. When I reviewed the X-ray taken last week and compared the images on file from 2012, there was no appreciable difference in more than nine years. In other words, the Platelets, Adult Mesenchymal Stem Cells, Precursor Cells, and Growth Factors in the Bone Marrow Concentrate successfully eliminated the symptoms and functional limitations secondary to osteoarthritis.
Limited Long-Term Outcomes Using Bone Marrow Concentrate, Until Now
Why this case is of special importance (actually, all patients are) has to do with the relative paucity of long-term outcomes using Bone Marrow Concentrate for osteoarthritis. In 2012, the belief and teaching revolved around the stem cell. More recently, we have recognized that the Growth Factors play an equally important role in the treatment of the arthritic joint, perhaps even more so than stem cells.
My scientific clinical research publications in the discipline of Regenerative Medicine have been based on one to four-year outcomes. This Blog’s subject may represent the longest clinical follow-up of a patient with an arthritic knee that has been treated with Bone Marrow Concentrate. While most patients want to know how quickly following a biologic intervention, they will experience symptom relief and functional improvement, equally or perhaps even more important is the long-term success of the cellular biologic procedure.
Since 2012, I have gathered evidence as to which biologic procedure is best suited for the needs of an arthritic joint. My care is evidence-based. The range of treatment options includes proprietary Platelet Rich Plasma, Bone Marrow Concentrate, Growth Factors, and Adipose-Derived Stem Cells, the latter made possible by my clinical research relationship with Personalized Stem Cells, Inc. While the first PSC FDA approved Clinical Trial for osteoarthritis of the knee has been completed, we hope to receive FDA approval for the next clinical trial.
To learn more about my Biologic Practice using a needle, not a knife for the treatment of arthritis, visit www.SheinkopMD.com. Schedule an appointment by calling (312) 475-1893. You may follow the announcement of the next Personalized Stem Cell FDA approved clinical trial for an arthritic joint at www.PersonalizedStemcells.com.